This is an exciting time for melanoma treatment, with a half-dozen new drugs approved in just over four years. This influx has brought a new complexity to the field, however, including questions about which drugs to give which patients, in what order to give those drugs, and in what combination they can be given. The rapid rise of immunotherapy drugs has introduced a new type of side effect profile that further complicates treatment. One overlooked result of these changes is the need for a new level of communication between patients and their health care team. Data is clear that patients who are well informed and well supported live longer and better, but what does that look like in the current treatment landscape.